Evidence map›Paper›PMID 39899125›Full record

ArticleMolecular diversity2025

Discovery of novel A

Ankit Singh, Amresh Prakash, Jyoti Mishra, Pratibha Mehta Luthra

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ankit Singh *Neuropharmaceutical Chemistry Laboratory, Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, 110007, India.
Amresh Prakash *Neuropharmaceutical Chemistry Laboratory, Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, 110007, India.
Jyoti MishraNeuropharmaceutical Chemistry Laboratory, Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, 110007, India.
Pratibha Mehta LuthraNeuropharmaceutical Chemistry Laboratory, Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, 110007, India. pmluthra@acbr.du.ac.in.

Funding

Council of Scientific and Industrial Research, India 191620036290Institution of Eminence (IoE), University of Delhi IoE/2023-24/12/FRPUniversity Grants Commission SCH/139/Non-NET /File no. 1818
6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder which is caused by abrupt degeneration of dopaminergic neuronal cells in the substantia nigra pars compacta (SNPc) area of the midbrain. Adenosine A

Indexed as

Adenosine A2 Receptor AntagonistsNeuroprotective AgentsParkinsonian DisordersQuantitative Structure-Activity RelationshipReceptor, Adenosine A2AAnimalsCell Line, TumorDrug DiscoveryHaloperidolHumansMaleMiceMice, Inbred C57BLMolecular Docking SimulationOxidopaminePharmacophoreAdenosine A2 Receptor AntagonistsHaloperidolNeuroprotective AgentsOxidopamineReceptor, Adenosine A2A3D-QSAR-Pharmacophore modeling6-OHDAA2AR antagonistsParkinson’s diseaseROSSH-SY5Y cells

Identifiers

PMID39899125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.